EMA Authorised: Nulojix (belatacept) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA authorised belatacept (Nulojix) for use in kidney transplant recipients to prevent graft rejection; the decision date was 16 April 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection

Drugs mentioned

• Nulojix (belatacept)

Snippet

Status: Authorised. Therapeutic area: Graft Rejection;Kidney Transplantation. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 16/04/2026